Phase II clinical trial of lastet capsule in combination chemotherapy of malignant tumors in China
Tóm tắt
This study reports the efficacy of prolonged administration of oral etoposide in the treatment of 86 cases with solid tumor, malignant lymphoma and other cancer. The oral etoposide used was the Lastet capsule (Las-c). An overall response rate (RR) of 62.8% was achieved with CR rate being 23.3% and PR rate 39.5%. Different combination chemotherapy regimens led to different response rates but no significant difference was found. The Las-C containing regimens used in this study have not caused any serious side effects.
Tài liệu tham khảo
1995; 22(1):2
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207.
Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: A phase II trial. J Clin Oncol 1992; 10:292.
Fridrik MA, Hausmaninger H, Michlmayr G, et al. Toxicity and preliminary results with a new Eight-Drug Regimen (ECOP-IMVP-DEXA) in the treatment of aggressive lymphomas. Hematol Oncol 1991; 9:209.
Furuse K. Platinum/oral etoposide therapy in non-small cell lung cancer. Oncology 1992; 49(Suppl 1):63.